Skip to main content

Norak Licenses Transfluor Technology to Merck

NEW YORK, Oct. 6 (GenomeWeb News) - Norak Biosciences has licensed its Transfluor technology to drug maker Merck for use in its G protein-coupled receptor drug discovery efforts.


Financial terms of the pact were not disclosed. The pact is the second between the firms, following a 2002 agreement granting Merck limited access to Transfluor, which is used to screen potential drug candidates against GPCR targets.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.